• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » The importance of demonizing specialists

The importance of demonizing specialists

February 14, 2014 By MassDevice

By Westby G. Fisher, MD, FACC

Westby Fisher

Most of us would agree that health care costs are too high in America.  They must be controlled or else we won’t have a sustainable health care system here.  And we should acknowledge that, on average, all doctors in America are paid higher than their overseas counterparts.  But we should also agree that expenses for doctors to earn a degree, maintain that degree and licensure, and pay their malpractice premiums is also much higher than the rest of the world.

So why has Elisabeth Rosenthal of the New York Times decided to bash specialists with her front page story entitled "Patients’ Costs Skyrocket;Specialists’ Incomes Soar"?  Perhaps the subtitle of the story explains part of the reason: "When a Doctor Becomes an Entrepreneur, Small Procedures Offer Big Returns."

We should acknowledge that several moons have aligned that make such an article newsworthy. 

First, of course, is the remarkably unaffordable Affordable Care Act.  The new law is confusing for patients (to say the least).  Not only are terms like deductibles, co-pays, subsidies, and co-insurance confusing, there is absolute uncertainty about which doctors or health care system can provide once their insurance is purchased.  Is a doctor "in-network" or "out-of-network?"  What, really, do I get for Platinum, Gold, Silver, or Bronze coverage?  How many mental health visits can a patient have with their particular policy? Because every one of the hundreds of different policies has different "rules," patients are left to fend for themselves like never before.  Patients are confused.  Doctors, having little clue about anything regarding such care limitations and cost structure, also have little understanding about the programs sold, so they become easy targets.

Second, is the current political pressure to develop physician payment reform.  It has long been known that health care was on an unsustainable cost path.  Numerous Congressional fiats have been used to control physician costs.  There was the Medicare Volume Performance Standard (MVPS), for instance, that was later replaced by the infamous and never-enforced Medicare Sustainable Growth Rate (SGR).  Why hasn’t Congress enforced their own law?  Simple: because doctors matter to seniors worried about health care and seniors vote.  Oh, and doctors take care of Congressmen, too.  But let’s not mention this, Ms. Rosenthal – you see Americans might think their doctors are actually worth their salaries.

Third, was the Stimulus Package, formerly known as the American Recovery and Reinvestment Act of 2009 used to bolster the American Economy.  Within the confines of this bill were several features that laid the groundwork to the later Affordable Care Act.  These included the Health Information Technology for Economic and Clinical Health Act (HITECH Act), another 25.8 billion for information technology, $1 billion for "health and wellness", $1.3 billion for "comparative effectiveness research" and (most important for specialists) a 40% cut to Medicare technical revenues to specialists who perform office-based procedures without a corresponding cut to similar fees paid to hospitals.  This final provision proved devastating to private specialist offices nationwide, forcing most of them to become employees of large health are systems.  The move was massive and has forever changed patients’ access to their physicians and elevated costs for them dramatically.  With such a move, doctors must now serve two masters: their employer and their patients.  All those pretty buildings, big screen TVs, administrator salaries, CEO salaries, and computer systems are very expensive.  Gee, who knew specialists’ bills would skyrocket as a result?  Yet according to Ms. Rosenthal, it’s the specialists’ fault.

But this is not the entire story.  While specialists’ bills have skyrocketed, their incomes have not.  I should know, because unlike Ms. Rosenthal, I am a real live US specialist and I have the W-2’s to prove it.  Again this year, another $20K less.

Why?  I believe this year’s cut was due to how I am paid.  (Because I am sworn to secrecy about such issues by my employment contract, I can’t delve into all the details, but let’s acknowledge to points: (1) productivity is important to employers since they want to get the "most bang for their buck," and (2)  most doctor’s work is "valued" based on a Medicare metric called "Relative Value Units." )

 This post is already too long to delve into details about how procedures are "valued" by the system, but suffice it to say, they are.  Every procedure has an RVU value.  The more you do, the more you get credit for.  This really bothers policy wonks who feel this is the single reason costs are so high in medicine.  Never is mentioned the next fact: that Medicare has a habit or "bundling" several procedure codes into one to cut costs already.  What does this mean for the doctor?  It means they earn fewer RVUs for the same work.  So doctors are spurned to do more and more to make up the difference.

Until they can’t any more.  After all, there are only so many hours in the day.
Last year my specialty had a huge change in RVU values for our expensive specialty, and because I am well-established, I have lots and lots of patients in my clinic.  Adding new ones has become nearly impossible.  But new patients means new procedures.  And without procedures, I invariably have my pay drop thanks to these hidden changes to how I am paid.

Finally, there’s the problem of Ms. Rosenthal’s salary data.  She received it from an industry-standard company that makes money reporting physician salaries to hospital systems.  They claim their data is based on physician salary surveys, but I for one can attest that I have NEVER been asked to reveal my salary to this company.  Could they be getting their data from hospital systems instead?  Of course. 

I have had the opportunity to inquire about the MGMA’s data for my sub-specialty of cardiac electrophysiology.  Their dataset supposedly represents only about 400 physician salaries (10%) of the entire nation’s 4000 or so electrophysiologists.  We have no idea where these data were collected.  Yet the salaries are stratified by RVU productivity into percentiles: 10%, 25%, 50%, 75% and 90% or better.  If you earn only a 10% RVU value, you are a dog in an employer’s eyes. If you are 90% or better, you are worshiped. 

But for electrophysiology, several interesting tidbits exist: to achieve a 90% RVU value, the MGMA says that doctors must achieve over 19,000 RVUs per year as a specialist. Now I work my fanny off.  I am on call every third week.  I cover four hospitals and do plenty of procedures.  I have never made that kind of RVU productivity as shown in the 90th percentile.  Not even close.  Might this be a unachievable carrot that is being dangled before specialists’ eyes?

I was so amazed by that statistic touted by the MGMA that I asked our hospital administrative leadership to identify who the institution (or doctor) was that was producing like that.  After all, if I could learn how they are producing, I might be able to  improve my efficiencies, right?  Yet because the MGMA’s "benchmarks" are proprietary property, no one could identify the physician producing like that.

Which brings me back to the salary figures Ms. Rosenthal quotes in her inflammatory front-page story in the New York Times.  They are non-transparent.  They are skewed and cherry-picked to make her point.  And while some salaries might be representative for some areas of the country, I suspect most are not – especially for those in competitive health care markets.  Ms Rosenthal never mentions the regional differences in physician salaries that exist.

It seems there remains a real need to demonize physicians, especially specialists, as we proceed in health care reform.  In a system that has devalued primary care so dramatically, perhaps this is a way to gain favor for a shift in salaries to the primary care doctors.  Perhaps it’s a need to cut costs for large hospital systems that jury-rig their compensation structures on non-transparent benchmarks like the MGMA.  Whatever the reason, specialists’ salaries, jacked up my hospital systems eager to hire the most marketable talent, will remain easy targets.  After all, it’s much easier to point the finger at specialists that struggle to see all of the new patients, than to acknowledge the shortcomings of the very system that has gotten us where we are today.

Case in point: Most hospital-system CEO’s in Chicago salaries exceed many millions of dollars. Salaries and benefits of pharmaceutical and insurance companies exceed ten times that of hospital system CEOs.

But better that Ms. Rosenthal doesn’t mention these salaries or the other infrastructure changes that have gotten us where we are today.   After all, it’s much easier take a cheap shot at specialists in the New York Times.

-Wes

Filed Under: Blog, Healthcare Reform, Hospital Care, News Well Tagged With: Dr. Wes, Electrophysiology

In case you missed it

  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world

RSS From Medical Design & Outsourcing

  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy